The CF RIA program will be led by an independent Steering Committee comprised of expert clinicians and research scientists in the field of CF. All applications will be reviewed and evaluated by the Steering Committee.

They will select up to 5 research projects for awards of up to USD$125,000 to conduct a mentored research project that can be completed within 24 months. The grant application requires the commitment of a supervising mentor.


Applications will be considered for non-clinical and clinical research including in vitro and in vivo research, epidemiological studies, outcome studies and interventional studies.

Therapeutic treatment studies proposed using Vertex marketed products, will be subject to additional review and approval.


Applications will be evaluated by the Steering Committee against the following selection criteria:

A. Quality of proposal

Innovation of research; feasibility of research; alignment to the CF RIA program’s research focus.

B. Ability of the PI to deliver the project

Experience and record of research center in therapeutic area; quality and availability of resources; adherence to ethical principles; mentor commitment; design, execution and monitoring of the research by the principal investigator; reasonable approach to budget.

C. Impact of project on understanding or treatment of CF


The CF RIA program is designed to support non-clinical and clinical research in CF and applications will be considered from across the entire field of CF.

PrivacyTerms of Use
© 2018 Vertex Pharmaceuticals Incorporated | VXMA-HQ-92-00065(2) | 02/2018
Vertex and the Vertex triangle logo are trademarks of Vertex Pharmaceuticals Incorporated
CF RIA program funding is supported by Vertex Pharmaceuticals Incorporated